Featured Research

from universities, journals, and other organizations

Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment

Date:
October 18, 2005
Source:
University of Pittsburgh Medical Center
Summary:
Treating breast cancer with MammoSite® resulted in a low risk of complications and was generally well tolerated, according to a University of Pittsburgh study. The study, presented at the 47th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Oct. 16 to 20, also evaluated cosmetic outcome of treatment with MammoSite and found that it was comparable to that of standard external beam radiation.

MammoSite, a type ofbreast brachytherapy (bray-kee-therapy), uses a single catheterinserted into the breast following lumpectomy, or surgical removal of atumor, to deliver a high dose of radiation. Once the catheter isinserted, a tiny balloon is inflated and loaded with radioactive seedsthat deliver prescribed levels of radiation to targeted tissuesurrounding the tumor site.

"MammoSite is a type of partialbreast irradiation that delivers radiation from the inside of thebreast directly to the tumor site where cancer cells are most likely toreside," said Sushil Beriwal, M.D., assistant professor at theUniversity of Pittsburgh School of Medicine and medical director ofradiation oncology at Magee-Womens Hospital of the University ofPittsburgh Medical Center (UPMC). "Ours is one of the largestsingle-institution studies to confirm that it does this safely and withan acceptable level of toxicity."

The study, which was designedto evaluate early outcomes of MammoSite brachytherapy, and was approvedby the FDA in 2002, evaluated toxicity in 100 patients treated betweenJune 2002 and October 2004 at the University of Pittsburgh CancerInstitute. The patients were followed between three and 30 monthssubsequent to treatment with an average follow-up time of one year.After treatment, patients were assessed at one week, one month and atthree-month intervals. While 14 percent of women had to have thecatheter removed because of various reasons, the majority of thepatients (86 percent) underwent treatment.

Post-treatmentcomplications included balloon rupture, infections, skin toxicity andseromas (persistence of the cavity where the lump was removed). Studyresults indicated that balloon rupture occurred in six patients (7percent) and wound infections occurred in 10 patients (12 percent). Nopatients had serious skin toxicities from treatment. A palpable seromawas observed in 34 of the patients (40 percent) and persisted beyondsix months of treatment in 22 patients (26 percent).

The studyalso evaluated cosmetic outcome of MammoSite treatment. Cosmeticoutcome refers to the physical similarity between the treated breastand the untreated breast. Forty-eight patients (56 percent) hadexcellent cosmetic outcomes; 32 patients (37 percent) had good cosmeticoutcomes; and seven patients (7 percent) had fair cosmetic outcomes.

"Ourfindings demonstrate that the toxicities associated with MammoSite weresimilar to results reported in the MammoSite brachytherapy registrytrial," said Dr. Beriwal. "The complications were acceptable and thecosmetic outcome was comparable to what we might see with standardexternal beam radiation." Dr. Beriwal added that follow-up studies willseek to assess the long-term effects as well as the efficacy of thetreatment compared with standard external beam radiation therapy andother types of breast brachytherapy.

###

MammoSite is manufactured by Cytyc Corporation based in Alpharetta, Ga.

Alsoinvolved in the study from the University of Pittsburgh's department ofradiation oncology were Anurag Agarwal, M.D.; Dwight E. Heron, M.D.;Jeffrey Falk, M.D., Ronald Johnson, M.D.; Robert Mogus, R.T.T.; HayeonKim, M.S.; Kristina Gerszten, M.D.; and Melvin Deutsch, M.D.


Story Source:

The above story is based on materials provided by University of Pittsburgh Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Medical Center. "Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment." ScienceDaily. ScienceDaily, 18 October 2005. <www.sciencedaily.com/releases/2005/10/051018075958.htm>.
University of Pittsburgh Medical Center. (2005, October 18). Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2005/10/051018075958.htm
University of Pittsburgh Medical Center. "Largest Single-institution Study Demonstrates Mammosite Is A Safe Breast Cancer Treatment." ScienceDaily. www.sciencedaily.com/releases/2005/10/051018075958.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) — Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins